Bringing genetic testing into the clinical management of people with MASLD: are we there yet?

IF 33 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-05-29 DOI:10.1016/j.jhep.2025.05.016

Luca Valenti, Hannes Hagström

{"title":"Bringing genetic testing into the clinical management of people with MASLD: are we there yet?","authors":"Luca Valenti, Hannes Hagström","doi":"10.1016/j.jhep.2025.05.016","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors’ contributions</h2>HH: Writing and editing. LV: Writing and editing.</section></section><section><section><h2>Financial support</h2>LV was supported by Italian Ministry of Health (Ministero della Salute), Ricerca Finalizzata 2021 RF-2021-12373889, Italian Ministry of Health, Ricerca Finalizzata PNRR 2022 “RATIONAL” PNRR-MAD-2022-12375656; The European Union, H2020-ICT-2018-20/H2020-ICT-2020-2 under grant agreement No. 101016726 - REVEAL, HORIZON-MISS-2021-CANCER-02-03 “Genial” under grant agreement “101096312”; Italian ministry of Research (MUR) PNRR – M4 - C2 “ASSET”; PRIN 2022 MUR: “DEFENDER”.HH: Support from the Swedish</section></section><section><section><h2>Declaration of Competing Interest</h2>HHs institutions have received research funding from Astra Zeneca, EchoSens, Gilead, Intercept, MSD, Novo Nordisk, Takeda and Pfizer. He has served as consultant, speaker or on advisory boards for Astra Zeneca, Bristol Myers-Squibb, Echosens, Ipsen, MSD and Novo Nordisk and has been part of hepatic events adjudication committees for Arrowhead, Boehringer Ingelheim, KOWA and Jazz Pharma.LV reports speaking fees from: Viatris, Novo Nordisk, GSK; consulting for: Novo Nordisk, Pfizer, Boehringer</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"48 1","pages":""},"PeriodicalIF":33.0000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2025.05.016","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Authors’ contributions

HH: Writing and editing. LV: Writing and editing.

Financial support

LV was supported by Italian Ministry of Health (Ministero della Salute), Ricerca Finalizzata 2021 RF-2021-12373889, Italian Ministry of Health, Ricerca Finalizzata PNRR 2022 “RATIONAL” PNRR-MAD-2022-12375656; The European Union, H2020-ICT-2018-20/H2020-ICT-2020-2 under grant agreement No. 101016726 - REVEAL, HORIZON-MISS-2021-CANCER-02-03 “Genial” under grant agreement “101096312”; Italian ministry of Research (MUR) PNRR – M4 - C2 “ASSET”; PRIN 2022 MUR: “DEFENDER”.HH: Support from the Swedish

Declaration of Competing Interest

HHs institutions have received research funding from Astra Zeneca, EchoSens, Gilead, Intercept, MSD, Novo Nordisk, Takeda and Pfizer. He has served as consultant, speaker or on advisory boards for Astra Zeneca, Bristol Myers-Squibb, Echosens, Ipsen, MSD and Novo Nordisk and has been part of hepatic events adjudication committees for Arrowhead, Boehringer Ingelheim, KOWA and Jazz Pharma.LV reports speaking fees from: Viatris, Novo Nordisk, GSK; consulting for: Novo Nordisk, Pfizer, Boehringer

查看原文本刊更多论文

将基因检测引入MASLD患者的临床管理：我们做到了吗？

部分片段作者贡献shh：写作和编辑。LV：写作和编辑。lv得到意大利卫生部（Ministero della Salute） Ricerca Finalizzata 2021 RF-2021-12373889、意大利卫生部Ricerca Finalizzata PNRR 2022“RATIONAL”PNRR- madr -2022-12375656的支持；欧盟，H2020-ICT-2018-20/H2020-ICT-2020-2（资助协议号：101016726 - REVEAL）， HORIZON-MISS-2021-CANCER-02-03“gentle”（资助协议号：101096312）；意大利研究部（MUR） PNRR - M4 - C2“ASSET”；2022年铭文：“后卫”。HH：来自瑞典竞争利益宣言的支持我们的机构已经获得了来自阿斯特拉-利康、EchoSens、吉利德、Intercept、默沙诺、诺和诺德、武田和辉瑞的研究经费。他曾担任Astra Zeneca、Bristol Myers-Squibb、Echosens、Ipsen、MSD和Novo Nordisk的顾问、发言人或顾问委员会成员，也是arrow、Boehringer Ingelheim、kova和Jazz Pharma的肝脏事件裁决委员会成员。LV报告的演讲费来自：Viatris、Novo Nordisk、GSK；咨询：诺和诺德，辉瑞，勃林格

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.